When it comes to long-term success with dividend investing, you need to focus on criteria beyond just yield. While some high yield dividend stocks can be worth the risk, there are plenty that are trading at a high yield for a good reason.
That is, either they are at risk of cutting or suspending their payouts, and/or other risks may lead to stock price declines that outweigh the returns generated by their large payouts. So, instead of focusing on yield alone, consider criteria such as dividend coverage and dividend growth, along with metrics like valuation.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Taking all of these into account, three blue chip dividend stocks stand out as strong, dare I say, "no brainer," buys right now: AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Procter & Gamble (NYSE: PG).
Several years ago, uncertainty ran high about AbbVie, mostly due to concerns about the impact of losing patent exclusivity for its flagship drug product, the rheumatoid arthritis treatment Humira. Yet while this did hurt AbbVie's revenue and earnings after exclusivity ended in 2023, the company has staged a comeback, largely thanks to the success of the anti-inflammatory drugs Skyrizi and Rinvoq.

#NYSE #abbvie #flashing

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.

#phase #revenue #Growth

Interested in AbbVie Inc.? Here are five stocks we like better.
SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in the fourth quarter and plans further combination-therapy data.
AbbVie is advancing a broad pipeline, including the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results and could support a rapid regulatory filing. Neuroscience programs such as bretisilocin for depression are also expected to deliver additional data this year.
The company is taking a selective approach to acquisitions and partnerships, having invested about $20 billion in roughly 30 transactions while increasing annual R&D spending toward $10 billion. Management maintained its outlook for high-single-digit annual revenue growth through the decade.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

#disease #company #Therapy

Altria (MO) and Chevron (CVX) anchor a three-stock dividend ladder that blends to a 4% yield and delivers a paycheck every month.
AbbVie's Skyrizi and Rinvoq each grew roughly 24% in Q2, fueling raised full-year EPS guidance and supporting a growing $1.73 quarterly dividend.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
Building a monthly income stream from quarterly dividend payers requires just a little scheduling. Three blue chips, staggered on different quarterly calendars, can deliver a paycheck in every month of the year. Altria (NYSE:MO) pays in January, April, July, and October. AbbVie (NYSE:ABBV) pays in February, May, August, and November. Chevron (NYSE:CVX) pays in March, June, September, and December. Together, these three tickers cover all 12 months while offering attractive dividends along the way.
Here is what each leg of the ladder actually pays, how it has grown, and where the risks sit.

#pays #Dividend #chevron #paycheck

For years, AbbVie (NYSE: ABBV) was known primarily for immunology. Humira built the company into a pharmaceutical giant, and newer blockbusters Skyrizi and Rinvoq have helped replace much of the revenue lost to biosimilar competition. Now the company's got another iron in the fire -- neuroscience -- and it's no slouch.
Management now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. That's a remarkable figure when you consider that the portfolio generated $10.8 billion last year and continues to grow at a double-digit pace.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Unlike some pharmaceutical franchises that depend on a single blockbuster, AbbVie's neuroscience business has become increasingly diversified. During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion. Schizophrenia and bipolar disorder drug Vraylar generated $1.07 billion, therapeutic Botox contributed $1.04 billion, and migraine drugs Ubrelvy and Qulipta combined for $742 million in quarterly sales. Parkinson's disease therapy Vyalev added another $256 million.
The fastest-growing part of AbbVie's neuroscience business may be migraine. Combined sales rose 22.6% year over year as Ubrelvy and Qulipta continued gaining traction with physicians addressing both acute migraine attacks and migraine prevention.

#year #billion #revenue #million

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08–$14.28.
Adding to its commercial trajectory, AbbVie's Allergan Aesthetics announced on July 17 that the European Commission approved Boey (trenibotulinumtoxinE) across all 30 European Economic Area countries. Marked as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, Boey targets the temporary improvement of moderate to severe frown lines with an onset as fast as eight hours and results lasting two to three weeks. This regulatory milestone follows approval in Canada earlier in the year and expands AbbVie's high-margin aesthetic portfolio beyond traditional Botox offerings.
Following these catalysts, Wall Street **** yst revisions have turned increasingly positive. On July 22, Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating. The firm updated its financial model ahead of Q2 earnings, citing expected strength across core prescription volume trends and recent positive developmental wins.
This momentum brings up a pivotal question: Does AbbVie's successful pivot away from legacy reliance justify higher valuation multiples, or do long-term debt levels and margin pressures cap future upside?
Proponents of the bullish case emphasize AbbVie Inc. (NYSE:ABBV)'s high-performing post-Humira growth engine. Top-line expansion is overwhelmingly driven by its flagship immunology **** ets, Skyrizi and Rinvoq, which generated $4.483 billion (+30.9% reported) and $2.119 billion (+23.3% reported) in Q1 net revenues, respectively. Rapid, durable share gains across multiple indication rollouts highlight a strong product-market fit that effectively absorbs legacy biosimilar erosion.

#diluted

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.
The filing rests on two Phase 3 studies, M21-416 and M21-417, both of which hit their main goal and showed statistically significant improvement in masseter prominence against a placebo, with p-values of 0.0046 and 0.0014. Twice as many treated patients called themselves satisfied compared with the placebo group, and the safety data lined up with Botox's long track record, with no new red flags. That is the AbbVie playbook in miniature: squeeze another approved use out of a drug it already owns rather than starting from zero.
The broader business backs that pattern up. In the quarter ended June 30, net revenue came in just under $17 billion, up more than 10% year over year, with immunology sales climbing 15% on Skyrizi and Rinvoq and neuroscience revenue jumping more than 20%. Management raised its full-year outlook for the second time this year, and the Humira patent-cliff drag that weighed on results for two years now looks largely behind the company.
Most of AbbVie's US product sales still flow through just three wholesale distributors, McKesson, Cardinal Health, and Cencora, a concentration that leaves the company exposed if any one relationship sours. The balance sheet carries real leverage too: a debt-to-equity ratio of roughly -21.1x as of its December 2025 filing means liabilities outweigh shareholder equity outright, and a current ratio near 0.7x offers less short-term cushion than many healthcare peers hold.
Patent protection for Skyrizi and Rinvoq remains a multi-year risk, and the Inflation Reduction Act already allows government price negotiation on products including Imbruvica and, notably, Botox itself. The pending $10.9 billion Apogee Therapeutics acquisition adds fresh debt and integration risk on top of that. Oncology revenue slipped almost 2% in the latest quarter, and the stock's 8% gain this year has trailed the S&P 500's 13%, with a trailing P/E near 70 that mostly reflects acquisition-related charges rather than the underlying business.

#revenue

SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.
AbbVie (ABBV) has guided total 2026 revenue to roughly $67.6 billion. About $21.7 billion of that, close to one-third, is expected to come from a single medicine, SKYRIZI. That share is the number a holder should sit with before anything else in this story.
The quarterly picture has the same shape. SKYRIZI sold $5.5 billion in the second quarter of 2026, up 24% operationally, against total net revenues of nearly $17 billion, and the next largest product AbbVie broke out, RINVOQ, sold more than $2.5 billion. Immunology as a whole brought in nearly $8.8 billion, more than half the company, on 14.6% operational growth. What makes that concentration matter is what sits beside it: oncology revenue of more than $1.6 billion fell 2.4% operationally in the same three months, and aesthetics, at nearly $1.3 billion, slipped 0.9%. Neuroscience did grow, at more than $3.2 billion and roughly 20%. So the growth you are paying for sits in immunology and neuroscience, and inside the bigger of the two it leans mostly on one molecule.
AbbVie does not have to imagine what biosimilar entry does to a large immunology franchise, because it is happening on its own income statement right now. HUMIRA sold $756 million in the second quarter of 2026, down 36% operationally, which the company puts down to biosimilar competition. A franchise shedding better than a third of its sales year over year is the shape of the risk, not its timing, because the two products sit on very different clocks.
SKYRIZI's clock is public and much further out. The company says the US composition-of-matter patent expires in 2033, that later-expiring patents embodying the product are granted or in process and run into the mid twenty-thirties and later, that regulatory data protection does not lapse until 2031, and that it does not expect biosimilar applications before the end of the decade. That is a long runway by any standard. It is also why the question keeps coming back, because close to a third of today's guided revenue eventually sits behind that later intellectual property rather than behind the original patent.

#billion #skyrizi #abbvie #behind

Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated **** et, as it can be administered monthly (the current leaders are taken weekly).

Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated ***** et, as it can be administered monthly (the current leaders are taken weekly).

When it comes to dividend stocks, no other sector has been more reliable than the healthcare sector. No matter the economic scenario, there will always be demand for drugs treating life-threatening diseases. This keeps the sector defensive, allowing large pharmaceutical companies to generate steady cash flow and consistently reward shareholders.
Two pharmaceutical giants — AbbVie (ABBV) and Eli Lilly (LLY) — stand out for some of the fastest-growing drug portfolios in the industry. However, only one is the better choice for income-seeking investors. Let's take a closer look.
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, ******* ysis, and headlines.
AbbVie is a global biopharmaceutical company that develops medicines for immunology, cancer, neuroscience, and aesthetics, with blockbuster drugs including Skyrizi, Rinvoq, and Botox. AbbVie's forward dividend yield of 2.65% is higher than the market and the healthcare sector average. This higher income compounds meaningfully over a decade, especially for investors who reinvest their dividends.
When AbbVie's top-selling drug, Humira, began losing patent protection, investors questioned whether it would weaken earnings and pressure dividends. However, the company has spent the last few years successfully replacing it, as Skyrizi and Rinvoq have become AbbVie's new growth engines, generating $6.6 billion in combined revenue in the first quarter of 2026.

With the S&P 500 looking historically expensive at 31 times earnings, it's a good time to buy a few defensive dividend stocks to hedge against a market crash. These stocks might also swoon during a downturn, but they'll reward patient investors with steady income. If you reinvest those dividends, you'll also accumulate more shares at lower prices.
The healthcare sector is a good place to find stable dividend stocks, as the market leaders usually generate ample cash and are well insulated from macro headwinds. These three pharma giants check those boxes and are arguably no-brainer income plays right now: AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE).
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie struggled after its blockbuster autoimmune disease drug, Humira, lost its U.S. patent exclusivity in 2023. But it offset that pressure with two newer immunology drugs, Skyrizi and Rinvoq, which it expects to generate combined sales of over $31 billion by 2027. It's also spent more than $20 billion on acquisitions over the past three years to diversify its portfolio.
AbbVie has raised its dividend every year since its spin-off from Abbott Laboratories (NYSE: ABT) in 2013. It currently pays a forward yield of 2.7%, and its dividends only consumed 59% of its free cash flow (FCF) over the past 12 months.

Pharmaceutical giant AbbVie (NYSE: ABBV) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE).
The deal would bring a promising immunology drug, zumilokibart, into AbbVie's pipeline. This is a drug that many see as competing with Dupixent from Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) as a treatment for moderate to severe atopic dermatitis, the most common form of eczema.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie said it would pay $135.11 a share in cash, a 49% premium to Apogee's closing price last week of $90.38. Here are two reasons to buy AbbVie stock if the deal goes through, and one reason to stand on the sidelines.
Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee acquisition provides immediate entry into next-generation targets. Apogee's lead **** et, zumilokibart, directly targets interleukin-13 (IL-13). This allows AbbVie to build a powerful clinical footprint in massive, high-margin indications such as atopic dermatitis and asthma, directly positioning it to challenge dominant market players.